Drug Price Rebates and 340B Changes Impact Pharmacy Manufacturers | Asembia AXS26
Drug pricing rules reshape pharmacy and manufacturer strategies, as transparency grows and 340B reforms intensify scrutiny.
Sabrina Aery, founder and principal of Aery Policy & Access Partners, explores how evolving drug pricing regulations, rebates, and federal programs are reshaping strategies for pharmaceutical manufacturers and pharmacies. Speaking from a manufacturer-focused consultancy perspective, Aery explains that for drugs subject to a maximum fair price (MFP), purchasing largely continues as usual, but there is now a critical float period between the acquisition cost and when rebates are received. Currently, rebates on MFP drugs take about 22 days on average, so pharmacies’ wholesaler payment terms (for example, 30-day payment windows) are key to managing cash flow and minimizing financial exposure.